Claims for Patent: 8,497,243

Summary for Patent: 8,497,243

Title:	Methods and compositions useful in the treatment of mucositis
Abstract:	In certain aspects, the present invention provides compositions and methods for treating mucositis.
Inventor(s):	Hesson; David Paul (Malvern, PA), Kramer; Michael Scott (Harleysville, PA)
Assignee:	Promedior, Inc. (Lexington, MA)
Application Number:	12/217,614
Patent Claims:	1. A method for treating, preventing or reducing the severity of mucositis in a patient, the method comprising administering, to a patient in need thereof, a therapeutically effective amount of Serum Amyloid P (SAP), wherein the SAP comprises protomers that are each at least 95% identical to the amino acid sequence of SEQ ID NO:1. 2. The method of claim 1, wherein administration of SAP delays the development of mucositis. 3. The method of claim 1, wherein administration of SAP reduces the number of days the patient is afflicted with mucositis. 4. The method of claim 1, wherein administration of SAP reduces the severity of mucositis by at least one grade, according to the National Cancer Institute-Common Toxicity Criteria. 5. The method of claim 1, wherein the mucositis is associated with radiation treatment, chemotherapy, or a combination thereof. 6. The method of claim 1, wherein the patient is at risk of developing mucositis. 7. The method of claim 6, wherein said administration commences prior to a treatment that places the patient at risk of developing mucositis. 8. The method of claim 6, wherein said administration commences concurrently with a treatment that places the patient at risk of developing mucositis. 9. The method of claim 6, wherein said administration commences after treatment that places the patient at risk of developing mucositis. 10. The method of claim 6, wherein the treatment that places the patient at risk of developing mucositis comprises radiation therapy, chemotherapy, or a combination thereof. 11. The method of any one of claims 1-10, wherein the patient is afflicted with cancer. 12. The method of any one of claims 1-10, wherein the patient is afflicted with head and neck, or breast, or lung or ovarian, prostate, or lymphatic, leukemic or gastrointestinal cancer. 13. The method of any one of claims 1-10, wherein the mucositis is oral mucositis. 14. The method of any one of claims 1-10, wherein the mucositis is gastrointestinal mucositis. 15. The method of any one of claims 1-10, wherein the mucositis is alimentary mucositis. 16. The method of any one of claims 1-10, wherein the mucositis is esophageal mucositis. 17. The method of claim 1, wherein the SAP increases SAP signaling. 18. The method of claim 1, wherein the SAP mimics SAP signaling. 19. The method of claim 1, wherein the SAP increases SAP activity. 20. The method of claim 1, further comprising administering a therapeutically effective amount of velafermin. 21. The method of claim 1, further comprising administering a therapeutically effective amount of palifermin. 22. The method of claim 1, wherein the SAP comprises protomers that are each at least 97% identical to the amino acid sequence of SEQ ID NO:1. 23. The method of claim 1, wherein the SAP comprises protomers that are each at least 99% identical to the amino acid sequence of SEQ ID NO:1. 24. The method of claim 1, wherein the SAP comprises protomers that each have the amino acid sequence of SEQ ID NO:1.

Details for Patent 8,497,243

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KEPIVANCE	palifermin	For Injection	125103	12/15/2004		2027-07-06